Loading...
Loading...
ADVM| Name | Value |
|---|---|
| Revenues | 1.0M |
| Cost of Revenue | 0.9M |
| Gross Profit | 0.1M |
| Operating Expense | 30.2M |
| Operating I/L | -30.7M |
| Other Income/Expense | 3.6M |
| Interest Income | 0.0M |
| Pretax | -27.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -27.1M |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company specializing in the development of gene therapy product candidates for ocular and rare diseases. Its lead product candidate, ADVM-022, is a single intravitreal injection gene therapy used to treat chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema. The company generates revenue through the development and potential commercialization of these gene therapy treatments. Adverum Biotechnologies, Inc. has established license and collaboration agreements with various institutions and companies to support its research and development efforts.
